NaSSA Antidepressant
Pregnancy: C
Mirtazapine (Elderly)
Brand names: Zispin SolTab, Mirtazapine
Adult dose
Dose: 15 mg once nightly initially; increase to 30–45 mg after 1–2 weeks
Route: oral
Frequency: once nightly
Max: 45 mg/day
Higher sedation at lower doses (H1 blockade predominates); less sedating at 30–45 mg; useful for depression with insomnia and weight loss
Paediatric dose
Route:
Not licensed for depression in children; limited evidence
Dose adjustments
Renal
Reduce dose in severe renal impairment
Hepatic
Reduce dose in hepatic impairment; avoid in severe
Clinical pearls
- Paradox: 15 mg more sedating than 30 mg due to dominant H1 blockade at lower doses; NE enhancement at higher doses counteracts sedation
- Excellent for elderly with poor appetite — weight gain is beneficial in malnourished patients
- No sexual dysfunction, no QT prolongation, no anticholinergic side effects — good tolerability profile for elderly
Contraindications
- Concurrent MAOIs
- Mania
Side effects
- Sedation/drowsiness
- Weight gain (5HT2 and H1 blockade)
- Dry mouth
- Constipation
- Increased appetite
- Agranulocytosis (rare)
- Hypertriglyceridaemia
Interactions
- MAOIs (serotonin syndrome)
- Alcohol/sedatives (enhanced CNS depression)
- CYP3A4 inhibitors (increase levels)
- Warfarin (may increase INR)
Monitoring
- Weight
- Lipids (long-term)
- Agranulocytosis symptoms (sore throat, fever)
- Mood assessment
Reference: BNFc; BNF 86; NICE NG222; BAP guidelines. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SCORE2-OP — 5/10-Year CVD Risk (Age ≥ 70) · Cardiovascular Risk
- Hearing Handicap Inventory for the Elderly — Screening (HHIE-S) · Hearing
- Clinical Frailty Scale (CFS) · Prognosis
- Confusion Assessment Method (CAM) · Cognitive Assessment
- Berg Balance Scale (BBS) · Rehabilitation
- Timed Up and Go (TUG) Test · Mobility Assessment
Pathways
- Falls Assessment in Older Adults · NICE CG161 2013
- Delirium Outside ICU · NICE CG103
- Comprehensive Geriatric Assessment (CGA) · BGS / NICE
- Delirium Assessment and Management · NICE CG103 2010
- Frailty Recognition and Management · BGS Frailty Framework / NHS NHSE
- Polypharmacy and Medicines Optimisation · STOPP/START v2 2014 / NICE NG5